Latest Healthcare Research Reports

Tag: genomic urine testing market demand

  • Genomic Urine Testing Market Expansion Is Reshaping Competitive Dynamics Across The Industry

    Genomic Urine Testing Market Expansion Is Reshaping Competitive Dynamics Across The Industry

    Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

    Genomic Urine Testing Market Revenue Growth Supported By A CAGR Of 1.79% Through 2030

    The market for genomic urine testing has experienced significant expansion lately. Projections indicate it will rise from a valuation of $1.01 billion in 2025 to $1.13 billion in 2026, reflecting a compound annual growth rate of 12.5%. Factors contributing to this historical growth trajectory include breakthroughs in molecular diagnostic technologies, an increasing demand for less invasive testing methods, pioneering research into early biomarkers, the wider integration of genomic assays by laboratories, and the overall expansion of the oncology diagnostics sector.

    The market for genomic urine testing is projected for substantial expansion in the coming years, anticipating a rise to $1.8 billion by 2030, driven by a compound annual growth rate of 12.2%. This growth trajectory is expected to be fueled by several key factors, including its incorporation into standard health check-ups, its broadened application in identifying infectious diseases, advancements in testing sensitivity, a growing need for individualized health monitoring, and ongoing clinical validation research. Furthermore, significant market shifts anticipated during this period involve a greater acceptance of diagnostic methods that do not require invasive procedures, an increased reliance on genomic markers for pinpointing diseases, a higher demand for early-stage cancer detection instruments, the wider implementation of tailored diagnostic strategies, and intensified investigations into the profiling of urinary genomics.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

    Genomic Urine Testing Market Growth Momentum: Which Factors Are Influencing Demand?

    The escalating challenge posed by chronic kidney disease is poised to fuel the expansion of the genomic urine testing market. This persistent condition, characterized by compromised kidney function and an inability to adequately cleanse the bloodstream, results in the accumulation of toxins and excess fluid. The growing prevalence of diabetes, a major contributor to this increase, exacerbates kidney damage as elevated glucose levels harm the delicate blood vessels within the kidneys, thereby hindering their filtering capacity. Genomic urine testing plays a crucial role in managing chronic kidney disease by facilitating the early identification of specific genetic indicators, which in turn enables prompt therapeutic actions and tailored management strategies. This leads to improved patient results through enhanced diagnostic precision and a mitigation of the disease’s advancement. Illustratively, based on a report from The American Journal of Managed Care in November 2025, an estimated 788 million adults in the United States, aged 20 and above, were identified as having CKD in the year 2023. Consequently, the expanding impact of chronic kidney disease serves as a significant impetus for the growth of the genomic urine testing sector.

    Genomic Urine Testing Market Segment Analysis And Revenue Opportunities

    The genomic urine testing market covered in this report is segmented –

    1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing

    2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies

    3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring

    4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users

    Subsegments:

    1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis

    2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection

    3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis

    4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing

    Genomic Urine Testing Market Trends Reshaping Industry Growth

    In the realm of genomic urine testing, key players are concentrating on forging pioneering approaches, including the implementation of next-generation sequencing (NGS), to elevate the precision, responsiveness, and early identification potential of non-invasive diagnostic methodologies for a spectrum of ailments. This sophisticated DNA sequencing technology, NGS, facilitates swift, precise, and extensive examination of genetic components by concurrently sequencing vast quantities of DNA segments. As an illustration, consider the introduction in May of 2023 by Convergent Genomics Inc., a biotechnology firm headquartered in the United States, of their genomic urine assay, UroAmp. Employing next-generation DNA sequencing, this test scrutinizes alterations in 60 genes linked to bladder cancer, thereby facilitating its early detection, potentially up to a dozen years prior to the manifestation of clinical signs. The assay furnishes comprehensive genetic intelligence to inform diagnostic processes, therapeutic choices, and the surveillance of disease recurrence, presenting a greater degree of accuracy compared to established techniques such as cytology and cystoscopy.

    Genomic Urine Testing Market Leading Players Shaping Industry Direction

    Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ?Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

    Access The Complete Genomic Urine Testing Market Report:

    https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

    Genomic Urine Testing Market Global Footprint: Which Region Holds Market Leadership?

    North Americawas the largest region in the genomic urine testing market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Genomic Urine Testing Market Expansion Is Reshaping Competitive Dynamics Across The Industry

    Genomic Urine Testing Market Expansion Is Reshaping Competitive Dynamics Across The Industry

    Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

    Genomic Urine Testing Market Revenue Growth Supported By A CAGR Of 1.79% Through 2030

    The market for genomic urine testing has experienced significant expansion lately. Projections indicate it will rise from a valuation of $1.01 billion in 2025 to $1.13 billion in 2026, reflecting a compound annual growth rate of 12.5%. Factors contributing to this historical growth trajectory include breakthroughs in molecular diagnostic technologies, an increasing demand for less invasive testing methods, pioneering research into early biomarkers, the wider integration of genomic assays by laboratories, and the overall expansion of the oncology diagnostics sector.

    The market for genomic urine testing is projected for substantial expansion in the coming years, anticipating a rise to $1.8 billion by 2030, driven by a compound annual growth rate of 12.2%. This growth trajectory is expected to be fueled by several key factors, including its incorporation into standard health check-ups, its broadened application in identifying infectious diseases, advancements in testing sensitivity, a growing need for individualized health monitoring, and ongoing clinical validation research. Furthermore, significant market shifts anticipated during this period involve a greater acceptance of diagnostic methods that do not require invasive procedures, an increased reliance on genomic markers for pinpointing diseases, a higher demand for early-stage cancer detection instruments, the wider implementation of tailored diagnostic strategies, and intensified investigations into the profiling of urinary genomics.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

    Genomic Urine Testing Market Growth Momentum: Which Factors Are Influencing Demand?

    The escalating challenge posed by chronic kidney disease is poised to fuel the expansion of the genomic urine testing market. This persistent condition, characterized by compromised kidney function and an inability to adequately cleanse the bloodstream, results in the accumulation of toxins and excess fluid. The growing prevalence of diabetes, a major contributor to this increase, exacerbates kidney damage as elevated glucose levels harm the delicate blood vessels within the kidneys, thereby hindering their filtering capacity. Genomic urine testing plays a crucial role in managing chronic kidney disease by facilitating the early identification of specific genetic indicators, which in turn enables prompt therapeutic actions and tailored management strategies. This leads to improved patient results through enhanced diagnostic precision and a mitigation of the disease’s advancement. Illustratively, based on a report from The American Journal of Managed Care in November 2025, an estimated 788 million adults in the United States, aged 20 and above, were identified as having CKD in the year 2023. Consequently, the expanding impact of chronic kidney disease serves as a significant impetus for the growth of the genomic urine testing sector.

    Genomic Urine Testing Market Segment Analysis And Revenue Opportunities

    The genomic urine testing market covered in this report is segmented –

    1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing

    2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies

    3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring

    4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users

    Subsegments:

    1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis

    2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection

    3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis

    4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing

    Genomic Urine Testing Market Trends Reshaping Industry Growth

    In the realm of genomic urine testing, key players are concentrating on forging pioneering approaches, including the implementation of next-generation sequencing (NGS), to elevate the precision, responsiveness, and early identification potential of non-invasive diagnostic methodologies for a spectrum of ailments. This sophisticated DNA sequencing technology, NGS, facilitates swift, precise, and extensive examination of genetic components by concurrently sequencing vast quantities of DNA segments. As an illustration, consider the introduction in May of 2023 by Convergent Genomics Inc., a biotechnology firm headquartered in the United States, of their genomic urine assay, UroAmp. Employing next-generation DNA sequencing, this test scrutinizes alterations in 60 genes linked to bladder cancer, thereby facilitating its early detection, potentially up to a dozen years prior to the manifestation of clinical signs. The assay furnishes comprehensive genetic intelligence to inform diagnostic processes, therapeutic choices, and the surveillance of disease recurrence, presenting a greater degree of accuracy compared to established techniques such as cytology and cystoscopy.

    Genomic Urine Testing Market Leading Players Shaping Industry Direction

    Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ?Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

    Access The Complete Genomic Urine Testing Market Report:

    https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

    Genomic Urine Testing Market Global Footprint: Which Region Holds Market Leadership?

    North Americawas the largest region in the genomic urine testing market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Genomic Urine Testing Market Expansion Is Reshaping Competitive Dynamics Across The Industry

    Genomic Urine Testing Market Expansion Is Reshaping Competitive Dynamics Across The Industry

    Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

    Genomic Urine Testing Market Revenue Growth Supported By A CAGR Of 1.79% Through 2030

    The market for genomic urine testing has experienced significant expansion lately. Projections indicate it will rise from a valuation of $1.01 billion in 2025 to $1.13 billion in 2026, reflecting a compound annual growth rate of 12.5%. Factors contributing to this historical growth trajectory include breakthroughs in molecular diagnostic technologies, an increasing demand for less invasive testing methods, pioneering research into early biomarkers, the wider integration of genomic assays by laboratories, and the overall expansion of the oncology diagnostics sector.

    The market for genomic urine testing is projected for substantial expansion in the coming years, anticipating a rise to $1.8 billion by 2030, driven by a compound annual growth rate of 12.2%. This growth trajectory is expected to be fueled by several key factors, including its incorporation into standard health check-ups, its broadened application in identifying infectious diseases, advancements in testing sensitivity, a growing need for individualized health monitoring, and ongoing clinical validation research. Furthermore, significant market shifts anticipated during this period involve a greater acceptance of diagnostic methods that do not require invasive procedures, an increased reliance on genomic markers for pinpointing diseases, a higher demand for early-stage cancer detection instruments, the wider implementation of tailored diagnostic strategies, and intensified investigations into the profiling of urinary genomics.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

    Genomic Urine Testing Market Growth Momentum: Which Factors Are Influencing Demand?

    The escalating challenge posed by chronic kidney disease is poised to fuel the expansion of the genomic urine testing market. This persistent condition, characterized by compromised kidney function and an inability to adequately cleanse the bloodstream, results in the accumulation of toxins and excess fluid. The growing prevalence of diabetes, a major contributor to this increase, exacerbates kidney damage as elevated glucose levels harm the delicate blood vessels within the kidneys, thereby hindering their filtering capacity. Genomic urine testing plays a crucial role in managing chronic kidney disease by facilitating the early identification of specific genetic indicators, which in turn enables prompt therapeutic actions and tailored management strategies. This leads to improved patient results through enhanced diagnostic precision and a mitigation of the disease’s advancement. Illustratively, based on a report from The American Journal of Managed Care in November 2025, an estimated 788 million adults in the United States, aged 20 and above, were identified as having CKD in the year 2023. Consequently, the expanding impact of chronic kidney disease serves as a significant impetus for the growth of the genomic urine testing sector.

    Genomic Urine Testing Market Segment Analysis And Revenue Opportunities

    The genomic urine testing market covered in this report is segmented –

    1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing

    2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies

    3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring

    4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users

    Subsegments:

    1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis

    2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection

    3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis

    4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing

    Genomic Urine Testing Market Trends Reshaping Industry Growth

    In the realm of genomic urine testing, key players are concentrating on forging pioneering approaches, including the implementation of next-generation sequencing (NGS), to elevate the precision, responsiveness, and early identification potential of non-invasive diagnostic methodologies for a spectrum of ailments. This sophisticated DNA sequencing technology, NGS, facilitates swift, precise, and extensive examination of genetic components by concurrently sequencing vast quantities of DNA segments. As an illustration, consider the introduction in May of 2023 by Convergent Genomics Inc., a biotechnology firm headquartered in the United States, of their genomic urine assay, UroAmp. Employing next-generation DNA sequencing, this test scrutinizes alterations in 60 genes linked to bladder cancer, thereby facilitating its early detection, potentially up to a dozen years prior to the manifestation of clinical signs. The assay furnishes comprehensive genetic intelligence to inform diagnostic processes, therapeutic choices, and the surveillance of disease recurrence, presenting a greater degree of accuracy compared to established techniques such as cytology and cystoscopy.

    Genomic Urine Testing Market Leading Players Shaping Industry Direction

    Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ?Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

    Access The Complete Genomic Urine Testing Market Report:

    https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

    Genomic Urine Testing Market Global Footprint: Which Region Holds Market Leadership?

    North Americawas the largest region in the genomic urine testing market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Genomic Urine Testing Market: Growth Drivers and Market Evolution

    Genomic Urine Testing Market: Growth Drivers and Market Evolution

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    By 2030, What Market Size Is The Genomic Urine Testing Market Expected To Reach Based On Its 2026 Value?

    The genomic urine testing market size has shown rapid expansion in recent years. It is anticipated to increase from $1.01 billion in 2025 to $1.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.5%. This historical growth can be attributed to advancements in molecular diagnostics, the necessity for non-invasive testing, foundational biomarker research, the adoption of genomic assays by laboratories, and the expansion of oncology diagnostics.

    The genomic urine testing market is anticipated to experience substantial growth over the next few years. It is forecast to achieve a valuation of $1.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.2%. This expansion during the forecast period is propelled by its integration into routine health screenings, its extended use for infectious disease detection, advancements in technological sensitivity, the increasing need for personalized monitoring, and successful clinical validation studies. Notable trends during this period include the rising acceptance of non-invasive diagnostic testing, an increased application of genomic biomarkers in disease detection, the growing requirement for early cancer screening tools, the broadening of personalized diagnostic methods, and intensified research efforts in urinary genomic profiling.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

    What Primary Drivers Are Shaping The Genomic Urine Testing Market?

    The rising prevalence of chronic kidney disease is anticipated to boost the expansion of the genomic urine testing market in the future. Chronic kidney disease (CKD) describes a state where kidney damage impairs their ability to filter blood, resulting in an accumulation of waste products and excess fluids within the body. This increase in the burden of CKD stems from the growing incidence of diabetes, given that elevated blood sugar levels harm renal blood vessels, compromising their waste-filtering capacity. Genomic urine testing contributes to CKD management by enabling the early identification of genetic indicators, facilitating prompt interventions and tailored treatment strategies. It improves patient results through more precise monitoring and by slowing the advancement of the disease. For instance, as reported in November 2025 by The American Journal of Managed Care, a US-based peer-reviewed medical publication, there were 788 million adults aged 20 and above living with CKD in 2023. Consequently, the escalating burden of chronic kidney disease is a primary catalyst for the growth of the genomic urine testing market.

    What Are The Main Segments Within The Genomic Urine Testing Market Segment Structure?

    The genomic urine testing market covered in this report is segmented –

    1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing

    2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies

    3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring

    4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users

    Subsegments:

    1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis

    2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection

    3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis

    4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing

    What Trends Are Affecting The Growth Of The Genomic Urine Testing Market?

    Major companies in the genomic urine testing market are focused on developing innovative solutions, such as next-generation sequencing, to enhance the accuracy, sensitivity, and early detection capabilities of non-invasive diagnostic tests for various diseases. Next-generation sequencing (NGS) is an advanced DNA sequencing technology that enables rapid, accurate, and large-scale analysis of genetic material by simultaneously sequencing millions of deoxyribonucleic acid (DNA) fragments. For instance, in May 2023, Convergent Genomics Inc., a US-based biotechnology company, launched the genomic urine test UroAmp. This test utilizes next-generation deoxyribonucleic acid (DNA) sequencing to analyze mutations in 60 genes associated with bladder cancer, allowing for early detection up to 12 years before clinical symptoms manifest. It provides detailed genetic insights to guide diagnosis, treatment decisions, and recurrence monitoring, offering higher accuracy than traditional methods like cytology and cystoscopy.

    Who Are The Companies Participating In The Genomic Urine Testing Market?

    Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ​Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

    Get The Full Genomic Urine Testing Market Report:

    https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

    Where Is The Genomic Urine Testing Market Primarily Concentrated By Region?

    North America was the largest region in the genomic urine testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Genomic Urine Testing Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

    Browse Through More Reports Similar to the Global Genomic Urine Testing Market 2026, By The Business Research Company

    Genetic Testing Services Market Report 2026

    https://www.thebusinessresearchcompany.com/report/genetic-testing-services-global-market-report

    Genetic Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

    Dna Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/dna-testing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Genomic Urine Testing Market Revenue Growth Expected to Reach $1.79 Billion by 2030 with 12.2% CAGR

    Genomic Urine Testing Market Revenue Growth Expected to Reach $1.79 Billion by 2030 with 12.2% CAGR

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Is The Market Size Of The Genomic Urine Testing Market In 2026 And What Value Is Projected For 2030?

    The genomic urine testing market has experienced rapid expansion in recent years. It is projected to increase from $1.01 billion in 2025 to $1.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.5%. The growth observed in the historical period stems from advances in molecular diagnostics, the demand for non-invasive testing, early biomarker research, the adoption of genomic assays by laboratories, and the overall growth in oncology diagnostics.

    The genomic urine testing market is anticipated to exhibit rapid expansion over the next few years, with its valuation expected to reach $1.8 billion in 2030, maintaining a compound annual growth rate (CAGR) of 12.2%. The projected growth within this period stems from its integration with routine health screening, an expansion into infectious disease detection, technological enhancements in sensitivity, the demand for personalized monitoring, and ongoing clinical validation studies. Significant trends during the forecast period include the increasing adoption of non-invasive diagnostic testing, a rising utilization of genomic biomarkers for disease detection, a growing need for tools for early cancer screening, the broadening of personalized diagnostic approaches, and increased research into urinary genomic profiling.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

    What Major Drivers Are Influencing Demand In The Genomic Urine Testing Market?

    The increasing prevalence of chronic kidney disease (CKD) is projected to drive the expansion of the genomic urine testing market. CKD is defined as a state where kidneys are compromised and can no longer effectively purify blood, leading to the accumulation of waste and fluids within the body. The escalating burden of CKD is linked to the rising occurrence of diabetes, as elevated blood sugar levels harm kidney blood vessels, thereby hindering their waste-filtering capacity. Genomic urine testing assists in CKD management by facilitating the early identification of genetic indicators, which allows for timely interventions and tailored treatment plans. It contributes to improved patient outcomes by enabling more accurate oversight and decelerating disease progression. For instance, in November 2025, according to The American Journal of Managed Care, a US-based peer-reviewed medical publication, 788 million adults aged 20 and older were living with CKD in 2023. Therefore, the growing burden of chronic kidney disease is a significant impetus for the growth of the genomic urine testing market.

    What Are The Key Segments Of The Genomic Urine Testing Market?

    The genomic urine testing market covered in this report is segmented –

    1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing

    2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies

    3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring

    4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users

    Subsegments:

    1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis

    2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection

    3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis

    4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing

    Which Upcoming Trends Are Expected To Influence The Genomic Urine Testing Market?

    Leading companies active in the genomic urine testing market are concentrating on developing advanced solutions, including next-generation sequencing, to improve the precision, responsiveness, and prompt identification features of non-invasive diagnostic tests for numerous conditions. Next-generation sequencing (NGS) is a sophisticated DNA sequencing technology that enables the swift, accurate, and extensive examination of genetic material by concurrently sequencing millions of deoxyribonucleic acid (DNA) fragments. For example, in May 2023, Convergent Genomics Inc., a US-based biotechnology firm, unveiled the genomic urine test UroAmp. This test employs next-generation deoxyribonucleic acid (DNA) sequencing to analyze mutations in 60 genes connected to bladder cancer, facilitating early detection up to 12 years before clinical symptoms emerge. It offers detailed genetic insights to direct diagnosis, inform treatment strategies, and monitor for recurrence, providing superior accuracy compared to conventional approaches like cytology and cystoscopy.

    Who Are The Leading Companies Operating In The Genomic Urine Testing Market?

    Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ?Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

    Read the full genomic urine testing market report here:

    https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

    Which Region Shows The Strongest Potential For Future Growth In The Genomic Urine Testing Market?

    North America was the largest region in the genomic urine testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Genomic Urine Testing Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=23408&type=smp

    Browse Through More Reports Similar to the Global Genomic Urine Testing Market 2026, By The Business Research Company

    Genomics Global Market Report

    https://www.thebusinessresearchcompany.com/report/genomics-global-market-report

    Genomics Personalized Health Global Market Report

    https://www.thebusinessresearchcompany.com/report/genomics-personalized-health-global-market-report

    Bioinformatics Global Market Report

    https://www.thebusinessresearchcompany.com/report/bioinformatics-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Genomic Urine Testing Market Future Outlook 2026: Key Drivers and Growth Potential

    Genomic Urine Testing Market Future Outlook 2026: Key Drivers and Growth Potential

    Uncover key drivers, emerging technologies, and competitive movements shaping the genomic urine testing market from 2026–2035 with trusted insights from The Business Research Company

    What level of CAGR-driven expansion is anticipated in the Genomic Urine Testing Market between 2026 and 2030?

    The genomic urine testing market has witnessed rapid growth in recent years. It is anticipated to expand from $1.01 billion in 2025 to $1.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.5%. This historical expansion can be attributed to advancements in molecular diagnostics, the increasing need for non-invasive testing, early biomarker research efforts, the adoption of genomic assays by laboratories, and the growth within oncology diagnostics.

    The genomic urine testing market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $1.8 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.2%. Factors contributing to this growth during the forecast period include its incorporation into standard health screenings, its extended application in identifying infectious diseases, advancements in technological sensitivity, the increasing need for personalized monitoring, and thorough clinical validation studies. Key trends anticipated for this period encompass a greater acceptance of non-invasive diagnostic methods, a surge in the application of genomic biomarkers for disease identification, an escalating requirement for early cancer screening instruments, the broadening of personalized diagnostic strategies, and enhanced research into urinary genomic profiling.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

    What Drivers Are Affecting Demand-Supply Dynamics In The Genomic Urine Testing Market?

    The expanding prevalence of chronic kidney disease (CKD) is anticipated to propel the future growth of the genomic urine testing market. Chronic kidney disease refers to a condition where damaged kidneys can no longer effectively filter blood, resulting in an accumulation of waste and fluids in the body. The burden of chronic kidney disease is increasing primarily due to the rising incidence of diabetes, as high blood sugar levels harm kidney blood vessels, thereby impairing their ability to filter waste efficiently. Genomic urine testing supports chronic kidney disease management by facilitating the early detection of genetic markers, which allows for timely interventions and tailored treatment plans. This technology improves patient outcomes by enabling more accurate monitoring and slowing down disease progression. For instance, in November 2025, according to The American Journal of Managed Care, a US-based peer-reviewed medical publication, it was reported that 788 million adults aged 20 and older were living with CKD in 2023. Therefore, the escalating burden of chronic kidney disease is a key driver for the growth of the genomic urine testing market.

    How Is The Genomic Urine Testing Market Organized Into Various Segments?

    The genomic urine testing market covered in this report is segmented –

    1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing

    2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies

    3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring

    4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users

    Subsegments:

    1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis

    2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection

    3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis

    4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing

    Which Trends Are Influencing The Development Of The Genomic Urine Testing Market?

    Leading companies in the genomic urine testing market are concentrating on developing innovative solutions, such as next-generation sequencing, to improve the accuracy, sensitivity, and early detection capabilities of non-invasive diagnostic tests for various diseases. Next-generation sequencing (NGS) is an advanced DNA sequencing technology that enables the rapid, precise, and large-scale analysis of genetic material by simultaneously sequencing millions of deoxyribonucleic acid (DNA) fragments. For instance, in May 2023, Convergent Genomics Inc., a US-based biotechnology company, unveiled the genomic urine test UroAmp. This test leverages next-generation deoxyribonucleic acid (DNA) sequencing to examine mutations in 60 genes associated with bladder cancer, facilitating early detection up to 12 years before clinical symptoms emerge. It offers detailed genetic insights to guide diagnosis, inform treatment decisions, and monitor recurrence, providing greater accuracy compared to traditional methods like cytology and cystoscopy.

    Who Are The Major Companies Operating In The Genomic Urine Testing Market?

    Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ?Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

    Which Region Is Anticipated To See The Fastest Growth In The Genomic Urine Testing Market?

    North America was the largest region in the genomic urine testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Genomic Urine Testing Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=23408&type=smp

    Browse Through More Reports Similar to the Global Genomic Urine Testing Market 2026, By The Business Research Company

    Genetic Testing Services Market Report 2026

    https://www.thebusinessresearchcompany.com/report/genetic-testing-services-global-market-report

    Genetic Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

    Dna Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/dna-testing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Which Emerging Trends Are Driving The Genomic Urine Testing Market Toward $1.61 Billion By 2029?

    Which Emerging Trends Are Driving The Genomic Urine Testing Market Toward $1.61 Billion By 2029?

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    What Are The Market Size Estimates For The Genomic Urine Testing Market?

    Rapid expansion has been a defining factor of the genomic urine testing market in the recent past. A predicted growth from $0.9 billion in 2024 to $1.01 billion in 2025, marked by a compound annual growth rate (CAGR) of 11.9%, further reflects this pattern. Several factors have informed this historic hike. They include a rising instance of urologic cancers, an escalating interest in early cancer detection, mounting consciousness around precision medicine, an advancing rate of genetic disorders, and expanding investments poured into biomarker discovery.

    The market size of genomic urine testing is set to experience a swift expansion in the upcoming years, predicted to reach $1.61 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.4%. Factors driving this growth during the prediction period include the growing implementation of liquid biopsy methods, an increased interest in personalized healthcare, an escalating incidence of chronic kidney ailments, a greater focus on at-home diagnostic tests, and a rising application of multi-omics methods in urine testing. Notable trends in the prediction period comprise the evolution of non-invasive diagnostic paths, creation of high-sensitivity test panels, incorporation of machine learning workflows, advancements in urine exosome segregation, and innovation surrounding single-cell urine sequencing.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

    Which Growth Drivers Are Shaping The Genomic Urine Testing Market Outlook?

    The escalating prevalence of chronic kidney disease is anticipated to stimulate the genomic urine testing market’s expansion. This disease is typified by kidney damage rendering them incapable of filtering blood effectively, hence resulting in waste and fluid accumulation in the body. The rise in diabetes instances, leading to high blood sugar levels that damage kidney blood vessels and hamper their waste filtration capability, are augmenting the burden of chronic kidney disease. Genomic urine testing proves beneficial in managing chronic kidney disease by allowing for early identification of distinct genetic markers and facilitating timely interventions and custom-tailored treatment strategies. It improves patient outcomes by allowing for more precise monitoring and curtailing disease advancement. For instance, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in June 2024 that the mortality rates for chronic kidney disease (CKD) increased from 4.2% in 2021 to 6.2% in 2022. Thus, the escalating prevalence of chronic kidney disease fuels the expansion of the genomic urine testing market.

    What Are The Primary Segmentation Parameters In The Genomic Urine Testing Market?

    The genomic urine testingmarket covered in this report is segmented –

    1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing; Ribonucleic Acid (RNA) Testing; Microbial Testing; Epigenetic Testing

    2) By Distribution Channel: Hospital Pharmacies; Mail Order Pharmacies; Speciality Pharmacies

    3) By Application: Cancer Diagnosis; Infectious Diseases; Genetic Disorder Screening; Health Monitoring

    4) By End-User: Hospitals And Clinics; Diagnostic Laboratories; Research And Academic Institutions; Other End Users

    Subsegments:

    1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis; Somatic Mutation Detection; Copy Number Variation (CNV) Testing; Single Nucleotide Polymorphism Analysis

    2) By Ribonucleic Acid Testing: Gene Expression Profiling; Messenger Ribonucleic Acid Analysis; Non-coding Ribonucleic Acid Detection; Fusion Transcript Detection

    3) By Microbial Testing: Urinary Microbiome Profiling; Pathogen Identification; Antimicrobial Resistance Gene Detection; Quantitative Microbial Load Analysis

    4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis; Histone Modification Profiling; Chromatin Accessibility Testing

    How Are Market Trends Influencing Competition In The Genomic Urine Testing Market?

    Leading businesses in the genomic urine testing market are concentrating on the creation of ground-breaking solutions, namely next-generation sequencing, to bolster the precision, sensitivity, and speed of early detection for non-invasive diagnostic tests used for various illnesses. The technique of next-generation sequencing (NGS) is a more evolved method of DNA sequencing that supports swift, detailed, and large-scale assessments of genetic materials by sequencing millions of DNA fragments all at once. For example, Convergent Genomics Inc., a biotech company from the US, introduced in May 2023, the UroAmp, a genomic urine test. This test used the novel DNA sequencing technique for examining alterations in 60 genes linked to bladder cancer, facilitating early detection of up to 12 years ahead of clinical symptom development. It offers comprehensive genetic perspectives which aid diagnosis, informs treatment choices, and monitors recurrence, proving more precise than conventional techniques such as cytology and cystoscopy.

    Which Organizations Are At The Forefront Of The Genomic Urine Testing Market?

    Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ​Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

    Which Region Holds The Greatest Opportunity For Genomic Urine Testing Market Expansion?

    North America was the largest region in the genomic urine testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=23408&type=smp

    Browse Through More Reports Similar to the Global Genomic Urine Testing Market 2025, By The Business Research Company

    Agrigenomics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/agrigenomics-global-market-report

    Ai In Genomics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/ai-in-genomics-global-market-report

    Blockchain In Genomics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/blockchain-in-genomics-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Genomic Urine Testing Market Forecast: What to Expect by 2029

    Genomic Urine Testing Market Forecast: What to Expect by 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    #What Is The Projected Market Size Of The Genomic Urine Testing Market By 2029?

    The genomic urine testing market has seen rapid expansion recently. This market is projected to increase from $0.9 billion in 2024 to $1.01 billion in 2025, at a compound annual growth rate (CAGR) of 11.9%. The historical growth can be attributed to several factors including the rising prevalence of urologic cancers, the increasing demand for early cancer detection, growing awareness of precision medicine, a higher incidence of genetic disorders, and increasing investments in biomarker discovery.

    The market for genomic urine testing is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $1.61 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.4%. This anticipated growth during the forecast period is fueled by factors such as the increasing uptake of liquid biopsy techniques, an intensified focus on personalized medicine, the escalating prevalence of chronic kidney diseases, a heightened emphasis on at-home diagnostic testing solutions, and the expanded application of multi-omics approaches in urine analysis. Key trends identified for the forecast timeframe encompass the development of non-invasive diagnostic methodologies, the creation of highly sensitive test panels, the integration of machine learning pipelines, advancements in urine exosome isolation, and innovations in single-cell urine sequencing.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

    What Are The Key Drivers Of Growth In The Genomic Urine Testing Market?

    The escalating burden of chronic kidney disease is projected to fuel the expansion of the genomic urine testing market moving forward. Chronic kidney disease refers to a state where the kidneys are damaged and can no longer effectively filter blood, resulting in a buildup of waste and fluids in the body. The increasing weight of chronic kidney disease is attributed to the rising occurrence of diabetes, as high blood sugar levels harm kidney blood vessels, impairing their ability to filter waste efficiently. Genomic urine testing assists in chronic kidney disease management by enabling the early detection of genetic markers, facilitating timely interventions and personalized treatment plans. It improves patient outcomes by allowing for more accurate monitoring and slowing down disease progression. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the chronic kidney disease (CKD) mortality rates increased from 4.2% in 2021 to 6.2% in 2022. Therefore, the intensifying burden of chronic kidney disease propels the growth of the genomic urine testing market.

    What Are The Segment Types Shaping The Genomic Urine Testing Market?

    The genomic urine testingmarket covered in this report is segmented –

    1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing; Ribonucleic Acid (RNA) Testing; Microbial Testing; Epigenetic Testing

    2) By Distribution Channel: Hospital Pharmacies; Mail Order Pharmacies; Speciality Pharmacies

    3) By Application: Cancer Diagnosis; Infectious Diseases; Genetic Disorder Screening; Health Monitoring

    4) By End-User: Hospitals And Clinics; Diagnostic Laboratories; Research And Academic Institutions; Other End Users

    Subsegments:

    1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis; Somatic Mutation Detection; Copy Number Variation (CNV) Testing; Single Nucleotide Polymorphism Analysis

    2) By Ribonucleic Acid Testing: Gene Expression Profiling; Messenger Ribonucleic Acid Analysis; Non-coding Ribonucleic Acid Detection; Fusion Transcript Detection

    3) By Microbial Testing: Urinary Microbiome Profiling; Pathogen Identification; Antimicrobial Resistance Gene Detection; Quantitative Microbial Load Analysis

    4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis; Histone Modification Profiling; Chromatin Accessibility Testing

    What Key Innovation Trends Are Fueling Advancements In The Genomic Urine Testing Market?

    Major companies within the genomic urine testing market are concentrating on developing advanced solutions, including next-generation sequencing, to improve the precision, sensitivity, and early detection capabilities of non-invasive diagnostic tests for a range of diseases. Next-generation sequencing (NGS) represents a sophisticated DNA sequencing technology that facilitates the rapid, accurate, and large-scale analysis of genetic material by simultaneously sequencing millions of deoxyribonucleic acid (DNA) fragments. For example, in May 2023, Convergent Genomics Inc., a US-based biotechnology company, introduced the genomic urine test UroAmp. This test employs next-generation deoxyribonucleic acid (DNA) sequencing to analyze mutations in 60 genes linked to bladder cancer, enabling early detection as much as 12 years before clinical symptoms manifest. It provides comprehensive genetic insights to guide diagnosis, inform treatment decisions, and monitor for recurrence, demonstrating superior accuracy compared to traditional methods such as cytology and cystoscopy.

    Which Leading Players Are Enhancing Their Genomic Urine Testing Market Presence Worldwide?

    Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ?Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

    Which Region Is Projected To Lead The Genomic Urine Testing Market During The Forecast Period?

    North America was the largest region in the genomic urine testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Genomic Urine Testing Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=23408&type=smp

    Browse Through More Reports Similar to the Global Genomic Urine Testing Market 2025, By The Business Research Company

    Agrigenomics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/agrigenomics-global-market-report

    Ai In Genomics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/ai-in-genomics-global-market-report

    Blockchain In Genomics Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/blockchain-in-genomics-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Top Trends Driving Innovation and Change in the Genomic Urine Testing Market: Next-Generation Sequencing Enhances Early Cancer Detection

    Top Trends Driving Innovation and Change in the Genomic Urine Testing Market: Next-Generation Sequencing Enhances Early Cancer Detection

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Current and Projected Market Size of the Genomic Urine Testing Market Through 2034?

    The market size for genomic urine testing has seen a swift expansion in the past few years. There will be a significant increase from $0.9 billion in 2024 to $1.01 billion in 2025, with a compound annual growth rate (CAGR) of 11.9%. Factors like the growing occurrence of urologic cancers, the heightened demand for early cancer detection, increased knowledge about precision medicine, the increasing rate of genetic disorders, and enhanced investments in biomarker discovery are responsible for the growth observed in the historic period.

    In the coming years, the size of the genomic urine testing market is projected to experience rapid expansion. It’s expected to reach$1.61 billion by 2029 at a compound annual growth rate (CAGR) of 12.4%. The anticipated growth during the forecast period can be credited to the increasing adoption of liquid biopsy methods, the escalating focus on tailor-made medicine, the swelling burden of chronic kidney ailments, the heightened emphasis on home-based diagnostic testing solutions, and the escalating use of multi-omics techniques in urine testing. The forecast period will also witness major trends like the creation of non-intrusive diagnostic routes, the development of highly sensitive test panels, the integration of machine learning workflows, advancements in urine exosome isolation, and innovations in single-cell urine sequencing.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

    What External and Internal Drivers Are Contributing to the Growth of theGenomic Urine Testing Market?

    The escalation in chronic kidney disease cases is predicted to fuel expansion of the genomic urine testing market. The term “chronic kidney disease” implies a situation where the kidneys are impaired and unable to effectively cleanse the blood, causing a waste accumulation and excess fluid. The increasing occurrence of diabetes, which damages the kidney blood vessels due to high blood sugar, elevates the chronic kidney disease burden, undermining the kidney’s waste filtering capability. Genomic urine testing helps manage chronic kidney disease by offering premature detection of genetic markers, enabling prompt interventions and individualized treatment schemes. It improves patients’ prognosis by allowing more precise surveillance and curtailing disease expansion. For instance, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in June 2024 that chronic kidney disease (CKD) mortality rates had escalated by 4.2% in 2021 to 6.2% in 2022. Thus, the mounting burden of chronic kidney disease stimulates the growth of the genomic urine testing market.

    What Segment Types Define the Genomic Urine Testing Market Structure?

    The genomic urine testingmarket covered in this report is segmented –

    1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing; Ribonucleic Acid (RNA) Testing; Microbial Testing; Epigenetic Testing

    2) By Distribution Channel: Hospital Pharmacies; Mail Order Pharmacies; Speciality Pharmacies

    3) By Application: Cancer Diagnosis; Infectious Diseases; Genetic Disorder Screening; Health Monitoring

    4) By End-User: Hospitals And Clinics; Diagnostic Laboratories; Research And Academic Institutions; Other End Users

    Subsegments:

    1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis; Somatic Mutation Detection; Copy Number Variation (CNV) Testing; Single Nucleotide Polymorphism Analysis

    2) By Ribonucleic Acid Testing: Gene Expression Profiling; Messenger Ribonucleic Acid Analysis; Non-coding Ribonucleic Acid Detection; Fusion Transcript Detection

    3) By Microbial Testing: Urinary Microbiome Profiling; Pathogen Identification; Antimicrobial Resistance Gene Detection; Quantitative Microbial Load Analysis

    4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis; Histone Modification Profiling; Chromatin Accessibility Testing

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=23408&type=smp

    Which Geographic Areas Hold the Strongest Growth Potential in the Genomic Urine Testing Market?

    North America was the largest region in the genomic urine testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Long-Term Trends Are Transforming the Competitive Landscape of the Genomic Urine Testing Market?

    Key players in the genomic urine testing market are focusing on the creation of groundbreaking solutions like next-generation sequencing, to enhance the precision, sensitivity and early identification capabilities of non-invasive diagnostic tests for a variety of ailments. Next-generation sequencing (NGS) is a superior DNA sequencing technology that facilitates quick, precise, and extensive examination of genetic material by simultaneously sequencing millions of DNA fragments. For example, in May 2023, the US-based biotechnology firm, Convergent Genomics Inc., introduced the genomic urine test UroAmp. This test utilizes next-generation DNA sequencing to recognize mutations in 60 genes related to bladder cancer, allowing for early detection, possibly up to 12 years prior to the manifestation of clinical symptoms. This provides comprehensive genetic insights that aid in diagnosis, treatment choices, and tracking recurrence, delivering higher accuracy compared to old-fashioned methods like cytology and cystoscopy.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

    What Is the Definition of the Genomic Urine Testing Market?

    Genomic urine testing is a non-invasive diagnostic method that analyzes genetic material present in urine to detect specific biomarkers related to diseases, such as cancer, infections, or genetic disorders. It combines genomics with advanced molecular techniques to identify mutations, gene expression patterns, or microbial deoxyribonucleic acid (DNA). The primary purpose is early detection, monitoring, and personalized treatment planning for various health conditions.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23408

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Genomic Urine Testing Forecast Report – Designed for Decision Makers and Product Teams

    Genomic Urine Testing Forecast Report – Designed for Decision Makers and Product Teams

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Growth Rate of the Genomic Urine Testing Market?

    The market size for genomic urine testing has seen a significant expansion in the last few years. Forecasts predict it will climb from $0.90 billion in 2024 to $1.01 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 12.9%. The surge in the historic timeframe is ascribed to the escalating occurrences of urologic cancers, the mounting requirement for early cancer detection, increased consciousness about precision medicine, a rising incidence of genetic disorders, and increased funding in biomarker discovery.

    What Growth Rate Is Forecasted for the Genomic Urine Testing Market by 2029?

    In the coming years, the genomic urine testing market is expected to experience significant growth, reaching a total worth of $1.62 billion by 2029, with an annual compound growth rate of 12.5%. The forecasted growth could be attributed to various factors including elevated adoption of liquid biopsy techniques, an increased focus on personalized medication, a surge in chronic kidney disease rates, a greater emphasis on home-based diagnostic testing alternatives, and an escalated use of multi-omics methods in urine testing. Some of the emerging trends during this period comprise the development of non-invasive diagnostic pathways, creation of test panels with high sensitivity, incorporation of machine learning frameworks, advancements in urine exosome isolation, and innovations in single-cell urine sequencing.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

    Which Key Companies Are Shaping the Future of the Genomic Urine Testing Market?

    Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ​Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

    Which Factors Are Driving Demand in the Genomic Urine Testing Industry?

    The growth of the genomic urine testing market is anticipated to be driven by the mounting burden of chronic kidney disease. Characterized as a condition where the kidneys become impaired, unable to effectively filter blood, leading to a toxic accumulation of waste and fluids in the body, chronic kidney disease is becoming increasingly prevalent due to the rising incidence of diabetes. This increase stems from the fact that elevated blood sugar levels can damage the blood vessels in the kidneys, thereby hampering their filtering capacity. Genomic urine testing proves invaluable in managing chronic kidney disease, offering early detection of genetic markers, thus enabling necessary interventions and a higher degree of personalization in treatment plans. Such testing results in more precise monitoring, mitigating disease advancement and improving patient outcomes. For example, the Australian Institute of Health and Welfare, an Australian government agency, highlighted a rise in chronic kidney disease mortality rates by 4.2% in 2021, reaching 6.2% in 2022. Thus, making the rise in chronic kidney disease a key driver for the expansion of the genomic urine testing market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=23408&type=smp

    How Is the Genomic Urine Testing Market Segmented by Several Divisions?

    The genomic urine testing market covered in this report is segmented –

    1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing

    2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies

    3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring

    4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users

    Subsegments

    1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis

    2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection

    3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis

    4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing

    What are the Emerging Market Trends Driving the Growth of the Genomic Urine Testing Industry?

    Top enterprises in the genomic urine testing market are honing their focus on the creation of novel solutions like next-generation sequencing, with the aim to boost precision, sensitivity, and the early identification potential of non-invasive diagnosis tests for a variety of diseases. Next-generation sequencing (NGS) represents a sophisticated technology for DNA sequencing, which makes the fast, correct and large-scale genetic material analysis possible by sequencing millions of DNA fragments at the same time. To illustrate, Convergent Genomics Inc., a biotech firm based in the US, introduced the genomic urine test UroAmp in May 2023. The test utilizes next-generation DNA sequencing to scrutinize mutations in 60 genes linked with bladder cancer, thus facilitating early detection as many as 12 years before clinical symptoms emerge. It offers thorough genetic insights for directing diagnosis, deciding treatment, and monitoring recurrence, hence delivering superior accuracy compared to conventional methods like cytology and cystoscopy.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

    Which Regions Are Driving Growth in the Genomic Urine Testing Market?

    North America was the largest region in the genomic urine testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23408

    This Report Delivers Insight On:

    1. How big is the genomic urine testing market, and how is it changing globally?

    2. Who are the major companies in the genomic urine testing market, and how are they performing?

    3. What are the key opportunities and risks in the genomic urine testing market right now?

    4. Which products or customer segments are growing the most in the genomic urine testing market?

    5. What factors are helping or slowing down the growth of the genomic urine testing market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model